Identifying Very Early Response to Seroquel Extended Release (XR) Augmentation for Major Depressive Disorder

This study has been completed.
Sponsor:
Collaborator:
AstraZeneca
Information provided by:
Sunnybrook Health Sciences Centre
ClinicalTrials.gov Identifier:
NCT00892463
First received: April 30, 2009
Last updated: July 27, 2011
Last verified: July 2011
  Purpose

The proposed study is for a 6 week open-label clinical trial in which Seroquel XR is added to a selective serotonin reuptake inhibitor (SSRI) medication for the treatment of depressive and/or anxiety symptoms. Each subject will self-report changes in symptoms, functional impairment, etc. on a twice daily basis using a handheld computer (HHC) that transmits real-time symptoms reports to a central database. Each subject will be assessed in-person on a weekly or biweekly basis during the course of the study.


Condition Intervention Phase
Depressive Disorder, Major
Drug: Quetiapine (Seroquel) XR
Phase 4

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Enhanced Identification of Very Early Response to Seroquel XR Added to an Antidepressant for the Treatment of Major Depressive Disorder With or Without Generalized Anxiety Disorder

Resource links provided by NLM:


Further study details as provided by Sunnybrook Health Sciences Centre:

Primary Outcome Measures:
  • The QIDS-SR16 (Quick Inventory of Depressive Symptomatology - Self-report) [ Time Frame: Once Daily for 6 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • HADS (Hamilton Anxiety Depression Scale) VADIS [ Time Frame: Once/twice Daily for 6 weeks ] [ Designated as safety issue: No ]

Enrollment: 26
Study Start Date: May 2009
Study Completion Date: December 2010
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Quetiapine (Seroquel) XR
    50mg/day - first 2 weeks 150mg/day - remaining 4 weeks min dose: 50mg/day max dose: 300mg/day
    Other Name: Seroquel XR
Detailed Description:

This study is a 6-week open-label clinical trial in which Seroquel XR is added to an antidepressant medication for the treatment of MDD with or without comorbid generalized anxiety disorder. Patients who are currently experiencing a depressive episode that has not responded to an adequate trial of an antidepressant will be eligible to participate. During the course of augmentation treatment with Seroquel XR, each subject will regularly enter information on symptom severity and functional impairment into their handheld computer, and this information will be wirelessly transmitted to a central database.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Diagnosis of major depressive disorder, currently depressed with or without a comorbid generalized anxiety disorder as determined by DSM-IV diagnostic criteria (confirmed using the MINI)
  2. Outpatient status
  3. 17-item Hamilton Depression Rating Scale (HAM-D) score of ≥ 18
  4. Treatment with any of the following antidepressant medications for the past 4 weeks at a minimum therapeutic dose

Exclusion Criteria:

  1. Diagnosis of a past or current bipolar disorder
  2. Current psychotic symptoms
  3. Substance-induced mood disorder
  4. Substance or alcohol dependence
  5. Prominent current suicidal ideation as defined by a HAM-D item 3 (suicide item) score of ≥ 3
  6. Current treatment with more than one antidepressant medication
  7. Current treatment with an tricyclic (TCA) antidepressant or monoamine oxidase inhibitor (MAOI)
  8. A patient with Diabetes Mellitus (DM)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00892463

Locations
Canada, Ontario
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada, M4N 3M5
Sponsors and Collaborators
Sunnybrook Health Sciences Centre
AstraZeneca
Investigators
Principal Investigator: Ayal Schaffer, MD Sunnybrook Health Sciences Centre - University of Toronto
  More Information

No publications provided

Responsible Party: Dr. Ayal Schaffer, Sunnybrook Health Sciences Centre
ClinicalTrials.gov Identifier: NCT00892463     History of Changes
Other Study ID Numbers: D1443L00072
Study First Received: April 30, 2009
Last Updated: July 27, 2011
Health Authority: Canada: Health Canada

Keywords provided by Sunnybrook Health Sciences Centre:
Major Depressive Disorder
Seroquel XR
Quetiapine

Additional relevant MeSH terms:
Depressive Disorder
Depression
Depressive Disorder, Major
Mood Disorders
Mental Disorders
Behavioral Symptoms
Quetiapine
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Psychotropic Drugs

ClinicalTrials.gov processed this record on July 23, 2014